KOD
Kodiak Sciences Inc.
$32.94
-3.29%
$2.1B
No data for this timeframe.
Vol
Market Cap$2.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$1.6B
Inst. Activity12 buys / 10 sells
Insider Activity0B / 2S
Insider Net $-$1.4M
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001468748·Prev Close $34.06
Recent Activity
Jun 11, 2026
SEC
Four mega-passive institutional investors (T. Rowe Price, Invesco, BofA, Morgan Stanley) aggressively accumulated Kodiak
INST-CLUSTER — Impact 4/10
Jun 4, 2026
Insider
BORGESON JOHN A. sold 25,896 shares
Chief Financial Officer @ $34.01 ($880.7K)
Jun 4, 2026
Insider
BORGESON JOHN A. acquired via exercise 30,000 shares
Chief Financial Officer @ $1.04 ($31.2K)
May 20, 2026
ftd
FTD: KOD — 21,418 shares ($0.7M) failed to deliver
Settlement: 20260520, Price: $34.42, FTD Value: $737,207.56, KODIAK SCIENCES INC COM
May 7, 2026
SEC
Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in lin
8-K — Impact 4/10
Apr 21, 2026
SEC
Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, driven by increased R&D s
8-K — Impact 8/10
Apr 15, 2026
Insider
BORGESON JOHN A. acquired via exercise 28,614 shares
Chief Financial Officer @ $1.04 ($29.8K)
Inst.
STATE STREET CORP — ADD
2,250,920 shares ($85.8M)
Price Targets
$62.67
+90.2% upside
Strong Buy
Current $32.94
Low $56.00
Median $59.50
High $80.00
6 analysts
$56.00
$80.00
Analyst Ratings
2Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Chardan Capital | UPGRADE | Neutral → Buy |
| Mar 27, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.96 ▲ +7.0% | $-0.99 — $-0.92 | 7% YoY | 6 |
| Next Q | $-0.93 ▲ +7.9% | $-1.04 — $-0.80 | 20% YoY | 6 |
| Current FY | $-3.74 ▲ +7.8% | $-4.03 — $-3.48 | 13% YoY | 6 |
| Next FY | $-3.12 ▲ +8.8% | $-3.50 — $-2.89 | 17% YoY | 5 |
Latest Reports
BULLISH
INST-CLUSTER
4/10
Four mega-passive institutional investors (T. Rowe Price, Invesco, BofA, Morgan Stanley) aggressively accumulated Kodiak
Jun 11, 2026
NEUTRAL
8-K
4/10
Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in lin
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BAKER BROS. ADVISORS LP | $759.3M | — |
| BlackRock, Inc. | $150.0M | ADD |
| STATE STREET CORP | $85.8M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $65.5M | — |
| GOLDMAN SACHS GROUP INC | $64.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | BORGESON JOHN | SELL | $880.7K |
| Jun 4, 2026 | BORGESON JOHN | M | $31.2K |
| Apr 15, 2026 | BORGESON JOHN | M | $29.8K |
| Apr 2, 2026 | BORGESON JOHN | M | $31.2K |
| Apr 2, 2026 | BORGESON JOHN | SELL | $496.8K |
50 institutional holders with $1.6B total value (41,245,992 shares) as of 2026-Q1. Top holders: BAKER, BlackRock,, STATE. Net buying activity: 12 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 19,919,186 | $759.3M | 48.3% | — |
| 2 | BlackRock, Inc. | 3,935,302 | $150.0M | 9.5% | ADD +33.9% |
| 3 | STATE STREET CORP | 2,250,920 | $85.8M | 5.5% | ADD +30.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,717,076 | $65.5M | 4.2% | — |
| 5 | GOLDMAN SACHS GROUP INC | 1,689,003 | $64.4M | 4.1% | — |
| 6 | RTW INVESTMENTS, LP | 1,487,934 | $56.7M | 3.6% | NEW |
| 7 | JANUS HENDERSON GROUP PLC | 1,325,457 | $50.5M | 3.2% | ADD +32.5% |
| 8 | CITADEL ADVISORS LLC | 870,788 | $33.2M | 2.1% | — |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 726,547 | $27.7M | 1.8% | DOUBLED +176.0% |
| 10 | Artisan Partners Limited Partnership | 690,322 | $26.3M | 1.7% | NEW |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 575,000 | $21.9M | 1.4% | TRIM -26.8% |
| 12 | MORGAN STANLEY | 515,864 | $19.7M | 1.3% | TRIM -26.3% |
| 13 | Point72 Asset Management, L.P. | 459,723 | $17.5M | 1.1% | NEAR_EXIT -78.8% |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 436,329 | $16.6M | 1.1% | DOUBLED +304.7% |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 365,051 | $13.9M | 0.9% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 349,803 | $13.3M | 0.8% | — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 315,400 | $12.0M | 0.8% | TRIM -36.8% |
| 18 | Invesco Ltd. | 305,074 | $11.6M | 0.7% | TRIM -45.0% |
| 19 | BANK OF AMERICA CORP /DE/ | 300,356 | $11.4M | 0.7% | ADD +52.7% |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 294,300 | $11.2M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 1,732,015 | 2,250,920 | +30.0% | $85.8M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 1,000,000 | 1,325,457 | +32.5% | $50.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 263,278 | 726,547 | +176.0% | $27.7M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 785,000 | 575,000 | -26.8% | $21.9M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 699,772 | 515,864 | -26.3% | $19.7M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 2,166,929 | 459,723 | -78.8% | $17.5M | 2026-Q1 |
| Invesco Ltd. | TRIM | 555,073 | 305,074 | -45.0% | $11.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 196,689 | 300,356 | +52.7% | $11.4M | 2026-Q1 |
| Trexquant Investment LP | TRIM | 190,505 | 123,402 | -35.2% | $4.7M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 91,508 | 120,629 | +31.8% | $4.6M | 2026-Q1 |
| Nuveen, LLC | ADD | 73,044 | 95,292 | +30.5% | $3.6M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 19,896 | 65,492 | +229.2% | $2.5M | 2026-Q1 |
| Jain Global LLC | NEAR_EXIT | 284,899 | 52,569 | -81.5% | $2.0M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 36,775 | 49,259 | +33.9% | $1.9M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | NEAR_EXIT | 180,718 | 29,717 | -83.6% | $1.1M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 19,529 | 29,348 | +50.3% | $1.1M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 2,918 | 20,173 | +591.3% | $769.0K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 31,717 | 18,629 | -41.3% | $710.2K | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 20,664 | 10,287 | -50.2% | $392.1K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 17,207 | 6,910 | -59.8% | $263.4K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 569 | 3,072 | +439.9% | $117.1K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 1,170,179 | 2,039,350 | +74.3% | $77.7K | 2026-Q1 |
| BlackRock, Inc. | ADD | 2,952,381 | 3,954,603 | +33.9% | $110.6M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 832,443 | 1,732,015 | +108.1% | $48.4M | 2025-Q4 |
| RTW INVESTMENTS, LP | NEW | — | 1,487,933 | — | $41.6M | 2025-Q4 |
2 unique insiders with 7 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | BORGESON JOHN A. | Chief Financial Officer | SELL | 25,896 | $34.01 | $880.7K |
| Jun 4, 2026 | BORGESON JOHN A. | Chief Financial Officer | EXERCISE | 30,000 | $1.04 | $31.2K |
| Apr 15, 2026 | BORGESON JOHN A. | Chief Financial Officer | EXERCISE | 28,614 | $1.04 | $29.8K |
| Apr 2, 2026 | BORGESON JOHN A. | Chief Financial Officer | EXERCISE | 30,000 | $1.04 | $31.2K |
| Apr 2, 2026 | BORGESON JOHN A. | Chief Financial Officer | SELL | 12,692 | $39.14 | $496.8K |
| Mar 25, 2026 | PERLROTH VICTOR | Chairman and CEO | EXERCISE | 300,000 | $1.04 | $312.0K |
| Mar 18, 2026 | PERLROTH VICTOR | Chairman and CEO | AWARD | 175,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BULLISH
INST-CLUSTER
4/10
Four mega-passive institutional investors (T. Rowe Price, Invesco, BofA, Morgan Stanley) aggressivel
Jun 11, 2026
NEUTRAL
8-K
4/10
Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025
May 7, 2026
BULLISH
8-K
8/10
Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, drive
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 2 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$62.67 mean target
+90.2% upside
Strong Buy (3.00)
$56.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $32.94 |
| Target Low | $56.00 |
| Target Mean | $62.67 |
| Target Median | $59.50 |
| Target High | $80.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.96 | $-0.99 | $-0.92 | 7.0% | +7.0% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.93 | $-1.04 | $-0.80 | 19.7% | +7.9% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-3.74 | $-4.03 | $-3.48 | 13.4% | +7.8% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-3.12 | $-3.50 | $-2.89 | 16.7% | +8.8% | 4↑ 0↓ | $0.1B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.958 | |
| 7d ago | $-1.030 | +0.072 |
| 30d ago | $-1.030 | +0.072 |
| 60d ago | $-0.760 | -0.198 |
| 90d ago | $-0.760 | -0.198 |
3 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Chardan Capital | UPGRADE | Neutral | Buy |
| Mar 27, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 2 | 7 | 2 | 1 | 0 | 75% | |
| Jan 1, 2026 | 2 | 6 | 3 | 1 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
ftd
FTD: KOD — 21,418 shares ($0.7M) failed to deliver
Settlement: 20260520, Price: $34.42, FTD Value: $737,207.56, KODIAK SCIENCES INC COM
May 18, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovasc
May 13, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Phase Phase 3 — COMPLETED
May 13, 2026
clinical_trial_readout
Results Pending: Tarcocimab (Phase 3) — Completed 89d ago
Trial: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovasc
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovasc
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Tarcocimab tedromer (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovasc
Apr 2, 2026
short_volume
Short Volume: KOD — 55.6% short (0.4M / 0.7M)
Short: 371,313 | Exempt: 20,766 | TRF Vol: 668,420 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_volume
Short Volume: KOD — 63.9% short (0.8M / 1.3M)
Short: 841,369 | Exempt: 474 | TRF Vol: 1,317,144 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: KOD — 59.1% short (0.7M / 1.1M)
Short: 677,272 | Exempt: 0 | TRF Vol: 1,145,058 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: KOD — 58.7% short (1.6M / 2.8M)
Short: 1,617,381 | Exempt: 8,045 | TRF Vol: 2,754,310 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings_calendar
KOD Q4 2025 Earnings After Market Close — 2026-03-26
Mar 26, 2026
short_volume
Short Volume: KOD — 69.1% short (4.1M / 6.0M)
Short: 4,122,765 | Exempt: 12,918 | TRF Vol: 5,963,097 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)